The effect of COVID-19 on patients recieving omalizumab treatment; [L'effet du COVID-19 sur les patients recevant un traitement par omalizumab]

Simple item page
dc.contributor.authorSayaca N.
dc.contributor.authorCansız K.A.
dc.contributor.authorYıldırım E.
dc.contributor.authorÖztürk B.
dc.contributor.authorKırmaz C.
dc.date.accessioned2024-07-22T08:03:02Z
dc.date.available2024-07-22T08:03:02Z
dc.date.issued2023
dc.description.abstractBackground and aim: Although exposure during drug administration and susceptibility to coronavirus disease-19 (COVID-19) infection secondary to immunomodulatory effects constitute potential risks for patients with chronic spontaneous urticaria (CSU) or asthma on omalizumab (OMZ), there is a risk of loss of response following discontinuation of OMZ. There are few studies describing the clinical course of COVID-19 in patients receiving OMZ. Materials and methods: A total of 103 patients on OMZ were included in the study between February 2021 and January 2022. Results: Fourteen (13.6%) of the patients participating in the study had SARS-CoV-2 infection, of whom 3 (21.4%) required hospitalization and 11 (78.6%) were treated in an outpatient clinic. During the pandemic, 17 (16.5%) of the patients interrupted their OMZ treatment. Patients on OMZ for six months or less had a lower rate of interruption (2.5%) than those on OMZ for more than 6 months (25.4%). Patients interrupted treatment for the following reasons: 3 (17.6%) had COVID-19, 10 (58.9%) did not attend the hospital visit due to concern about contamination with SARS-CoV-2, and 4 (23.5%) thought that OMZ treatment would facilitate contamination with SARS-CoV-2. After interrupting OMZ, 3 (25%) female patients and 5 (100%) male patients presented no worsening of their symptoms. Three (13%) of the patients on OMZ for asthma and 11 (13.8%) of those on the drug for urticaria had COVID-19 infection. Patients presenting CSU and severe asthma are completely different, with different potential consequences of OMZ interruption. Nine (52.9%) patients had aggravated symptoms following interruption of OMZ treatment. Three of them described worsening of asthma symptoms and a need to increment their maintenance therapy due to asthma exacerbation after nearly three weeks of interruption, and 6 of them had hives and pruritus as urticaria exacerbation nearly four weeks after interruption of OMZ. The asthma patients did not stop their other treatments, including inhaled corticosteroids. Conclusion: Use of OMZ does not increase the risk of SARS-CoV-2 infection, COVID-19-related pneumonia, or COVID-19-related hospitalization. We advise patients not to interrupt OMZ treatment during the COVID-19 pandemic unless advised to do so by their doctors, and we recommend that they receive instruction concerning self-administration of OMZ to avoid visiting hospitals in the event of a pandemic. © 2023 Elsevier Masson SAS
dc.identifier.DOI-ID10.1016/j.reval.2023.103281
dc.identifier.issn18770320
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12080
dc.language.isoEnglish
dc.publisherElsevier Masson s.r.l.
dc.rightsAll Open Access; Bronze Open Access
dc.subjectcorticosteroid
dc.subjectomalizumab
dc.subjectadult
dc.subjectArticle
dc.subjectasthma
dc.subjectchronic spontaneous urticaria
dc.subjectcomorbidity
dc.subjectcomputer assisted tomography
dc.subjectcontrolled study
dc.subjectcoronavirus disease 2019
dc.subjectdiabetes mellitus
dc.subjectdisease course
dc.subjectdisease exacerbation
dc.subjectfemale
dc.subjecthospitalization
dc.subjecthuman
dc.subjecthypertension
dc.subjectmaintenance therapy
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoutpatient care
dc.subjectpandemic
dc.subjectpruritus
dc.subjectsevere asthma
dc.subjectsymptom
dc.subjecttreatment interruption
dc.subjecturticaria
dc.titleThe effect of COVID-19 on patients recieving omalizumab treatment; [L'effet du COVID-19 sur les patients recevant un traitement par omalizumab]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu